Financings Ambit Biosciences Inc. set terms for its proposed IPO, aiming to raise $65 million. Anacor Pharmaceuticals Inc. completed its public offering for gross proceeds of $23 million. Celator Pharmaceuticals Inc. raised $32.5 million in a final closing of its private placement. Epizyme Inc. filed an S-1 for a proposed $69 million IPO. GW Pharmaceuticals plc priced its IPO of 3.5 million American Depository Shares at $8.90 per ADS. Idera Pharmaceuticals Inc. priced a public offering for gross

TOTAL: $103.52M Company (Location) Type Of Financing Number Of Shares, Units Or Warrants (M) Amount Raised (M) Investors; Placement Agents; Details Date Anthera Pharmaceuticals Inc. (Hayward, Calif.) Common stock purchase agreement N/A $2 Anthera entered an $18.5M common stock purchase agreement with Lincoln Park Capital Fund LLC, under which it made an initial purchase of $2M in common stock priced at 64.8 cents apiece 4/9/13 Cardium Therapeutics Inc. (San Diego) Private placement of

Partnerships are a key component in the operating playbook of emerging and developing biotechnology companies. Although this year is shaping up as a very big one for deals, according to data from the Biotechnology Industry Organization (BIO) and biopharma consulting firm Campbell Alliance Group, they are not as lucrative for generating cash in the early stages as they once were. Deal structures now emphasize a heavy dose of risk-sharing with downstream performance milestones and smaller upfront

Company Amount Raised Auris Medical AG $50.8M Jounce Therapeutics Inc. $47M Opsona Therapeutics Ltd. $43.2M Radius Health Inc. $43M GenSight Biologics $41.6M Esperion Therapeutics Inc. $33M Revance Therapeutics Inc. $33M Syros Pharmaceuticals $30M Labrys Biologics Inc. $31M Versartis Inc. $25M

I. COMMENCED TRADING IN APRIL Company (Symbol)# Date Filed Date Comm. Shares/ Units (M) Price Shares Out (M)@ Lead, Other Underwriters Gross (US$M) Post- Offering Market Cap (M)% INITIAL OFFERINGS Chimerix Inc. (Research Triangle Park, N.C.; CMRX)1 3/8/13 4/11/13 7.32S $14 24.4 Morgan Stanley Cowen & Co. (co-lead) William Blair Lazard Capital Markets $102.5 $341.6 Omthera Pharmaceuticals Inc. (Princeton, N.J.; OMTH)2 3/8/13 4/12/13 8S $8 24.4 BofA Merrill Lynch Barclays (co-lead

"There are very good early stage venture capitalists. But, as the pathway to approval under the FDA becomes longer and more expensive, it requires either a significant amount of long-term-view strategic focus to get through that pathway, or a significant amount of capital or both." – Luke Düster, principal with Capital Royalty L.P., on the closing of the firm's second fund "Phase I is a great time to buy if you're a pharma company. I think there's a lot of motivation for sellers to go as far as

Total: $416.95M Company Location Amt. (M) Details Date ActoGeniX NV Ghent, Belgium €10.7 ($14) ActoGeniX closed a Series B round, raising $14M, led by Saffelberg Investment, with the company's founders and GIMV, Biotech Fund Flanders, Baekeland Fund, BioVest CVA, Life Sciences Partners, Aescap Ventures and Ventech 4/19/13 Allecra Therapeutics GmbH Lorrach, Germany €15 ($19.6) Allecra raised $19.6M in a Series A round from Edmond de Rothschild Investment Partners, Forbion Capital Partners and

A report from real estate firm Jones Lang LaSalle in March lists San Diego as the number two biotechnology cluster in the U.S. Like any list, the ranking is debatable, especially by people in the San Francisco Bay Area who came in third. But whether the region is ranked first, second, or third, it's pretty clear San Diego and the rest of Southern California is an important region for the biotech industry. At the helm, serving as a guiding force, is Biocom, the 25-year old, including predecessors

By taking a detailed look at toxicities of a bispecific antibody that targets the transferrin receptor to cross the blood-brain-barrier, researchers at Genentech Inc. have gained new insights into both "important safety concerns and potential mitigation strategies" for the therapeutic development of such antibodies. The current studies, which were published in the May 2, 2013, issue of Science Translational Medicine, came out of work published in 2011 describing an antibody with two binding

Company Amount Raised Ironwood Pharmaceuticals Inc. $175M OPKO Health Inc. $175M Mesoblast Ltd. $174.6M Pacira Pharmaceuticals Inc. $110M e-Therapeutics plc $62.66M

The FDA's Oncologic Drugs Advisory Committee (ODAC) voted 13-1 against the adequacy of AVEO Oncology Inc.'s single Phase III trial to support the approval of tivozanib.

Total: $85.5M Year to Date: $204.55M Company (Location) Partner (Location) Amt. (M) Details Date Arena Pharmaceuticals Inc. (San Diego) Eisai Inc. (Woodcliff Lake, N.J.) $0.5 For the submission of a marketing authorization application for Belviq in Mexico for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults 4/2/13 Furiex Pharmaceuticals Inc. (Morrisville, N.C.) Menarini Group (Florence, Italy) $5 For the launch of Priligy in